Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - LadRx (Details)

v3.23.2
Royalty and Commercial Payment Purchase Agreements - LadRx (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 21, 2023
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs   $ 14,650 $ 5,000  
Contingent consideration under RPAs, AAAs and CPPAs   1,000   $ 75
Long-term royalty and commercial payment receivables   72,232   $ 63,683
Assignment and Assumption Agreement and Royalty Purchase Agreement        
Agreements        
Long-term royalty and commercial payment receivables $ 6,000      
LadRx        
Agreements        
Contingent consideration under RPAs, AAAs and CPPAs 1,000      
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement        
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs 5,000      
Maximum payments based on achievement of regulatory and commercial sales milestones 6,000      
Maximum payable on regulatory milestone 5,000      
Maximum payable on commercial sales milestone 1,000      
Amount of allowance for credit losses   $ 0    
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones        
Agreements        
Contingent consideration under RPAs, AAAs and CPPAs 1,000      
LadRx | Assignment and Assumption Agreement | Arimoclomol        
Agreements        
Maximum regulatory and commercial milestone payments, net 52,500      
Maximum payment obligations based on a portion of regulatory and commercial milestone payments 9,500      
LadRx | Royalty Purchase Agreement        
Agreements        
Contingent consideration under RPAs, AAAs and CPPAs 1,000      
LadRx | Royalty Purchase Agreement | Aldoxorubicin        
Agreements        
Maximum regulatory and commercial milestones $ 342,700